Administration of a dietary supplement ( N-oleyl-phosphatidylethanolamine and epigallocatechin-3-gallate formula) enhances compliance with diet in healthy overweight subjects: a randomized controlled trial.
Many studies have found that N-oleyl-ethanolamine (NOE), a metabolite of N-oleyl-phosphatidylethanolamine (NOPE), and epigallocatechin-3-gallate (EGCG) inhibit food intake. The main aim of this study was to evaluate the efficacy of 2 months of administration of an oily NOPE-EGCG complex (85 mg NOPE and 50 mg EGCG per capsule) and its effect on compliance with diet in healthy, overweight people. Secondary end-points of the study were to compare body composition, metabolic parameters, sensation of appetite, depressive symptoms and severity of binge eating. Using a parallel-arm, double-blind, placebo-controlled design, 138 healthy, overweight women (106) and men (thirty-two) were randomly assigned to one of two groups: (1) the treatment group (seventy-one patients: fifty-three females, eighteen males) taking two capsules per day of an oral supplement or (2) the placebo group (sixty-seven patients: fifty-three females, fourteen males). Both groups observed a 3344 kJ/d energy restriction. All parameters were assessed both before onset and after 2 months on the supplement. Dropout was 6 % in the NOPE-EGCG group and 27 % in the placebo group (P < 0.001). The treatment induced a significant weight reduction in both groups ( - 3.28 kg and - 2.67 kg in NOPE-EGCG and placebo, respectively); the weight changes were not significantly different between the groups. NOPE-EGCG treatment improved insulin resistance (P < 0.001), the sensation feelings of fullness (P < 0.05), depressive symptoms (P < 0.004) and severity of binge eating (P < 0.0001).
Rondanelli
Mariangela
M
Section of Human Nutrition and Dietetics, Department of Applied Health Sciences, Faculty of Medicine, University of Pavia, Pavia, Italy. serv.nutrizione@asppavia.it
Opizzi
Annalisa
A
Solerte
Sebastiano Bruno
SB
Trotti
Rosita
R
Klersy
Catherine
C
Cazzola
Roberta
R
D000293:Adolescent; D000328:Adult; D001067:Appetite Depressants / Q000008:administration & dosage*; D015415:Biomarkers / Q000097:blood; D001786:Blood Glucose / Q000032:analysis; D001823:Body Composition; D002392:Catechin / Q000008:administration & dosage / Q000031:analogs & derivatives*; D003863:Depression; D004038:Diet, Reducing; D019587:Dietary Supplements; D004311:Double-Blind Method; D004435:Eating; D005260:Female; D006801:Humans; D007328:Insulin / Q000097:blood; D008297:Male; D008875:Middle Aged; D050177:Overweight / Q000097:blood / Q000178:diet therapy*; D010349:Patient Compliance; D010714:Phosphatidylethanolamines / Q000008:administration & dosage; D012527:Satiation; D018709:Statistics, Nonparametric; D015431:Weight Loss
D001067:Appetite Depressants; D015415:Biomarkers; D001786:Blood Glucose; D007328:Insulin; C541208:N-oleyl-phosphatidylethanolamine; D010714:Phosphatidylethanolamines; D002392:Catechin; C045651:epigallocatechin gallate